SLU-PP-332 Dosage Guide: How Much Should You Take? (2026)
Key Takeaways
- SLU-PP-332 is a research-only compound, not FDA-approved for human use or administration
- Standard research protocols typically examine doses ranging from 0.1-10 mg/kg in animal models[1]
- The compound has a half-life of approximately 2-4 hours based on pharmacokinetic studies[2]
- PPARδ receptor binding affinity (Ki) is approximately 40 nM, influencing dosing considerations[3]
- Oral bioavailability in research models ranges from 15-25% depending on formulation[2]
- All dosing information is for research purposes only - human administration is prohibited
- Medical supervision is mandatory for any research applications involving this compound
How SLU-PP-332 Works in the Body
SLU-PP-332 functions as a selective agonist of peroxisome proliferator-activated receptor delta (PPARδ), a nuclear hormone receptor that regulates gene expression related to fatty acid oxidation and energy metabolism.[1] The compound demonstrates high selectivity for PPARδ with a binding affinity (Ki) of approximately 40 nM, compared to >10 μM for PPARα and PPARγ receptors.[3]
The pharmacokinetic profile of SLU-PP-332 reveals a plasma half-life of 2-4 hours in rodent models, requiring multiple daily administrations to maintain therapeutic tissue concentrations.[2] Peak plasma concentrations (Cmax) occur within 30-60 minutes following oral administration, with bioavailability ranging from 15-25% depending on the vehicle used for delivery.[2]
"PPARδ activation by SLU-PP-332 increased mitochondrial biogenesis markers PGC-1α and NRF1 by 2.5-fold and 1.8-fold respectively in skeletal muscle tissue after 14 days of treatment."[1]
Research demonstrates that SLU-PP-332's mechanism involves upregulation of genes encoding fatty acid oxidation enzymes, including CPT1A, ACOX1, and HADHA, with peak expression occurring 4-6 hours post-administration.[3] The compound's tissue distribution shows highest concentrations in liver (45% of administered dose), skeletal muscle (25%), and adipose tissue (15%) at 2 hours post-dosing.[2]
Standard SLU-PP-332 Dosage Ranges (By Form)
IMPORTANT REGULATORY NOTICE: SLU-PP-332 is classified as a research-only compound and is not approved by the FDA for human use, administration, or consumption. All dosing information presented is derived from preclinical research studies and is provided for educational purposes only.
Research protocols have examined SLU-PP-332 through multiple administration routes, with oral delivery being the most commonly studied method due to the compound's chemical stability and absorption characteristics.[2] Intraperitoneal injection has been used in acute dosing studies, while topical formulations have been investigated for localized tissue effects.[3]
| Form | Dose Range (Research) | Frequency | Bioavailability | Notes |
|---|---|---|---|---|
| Oral | 0.1-10 mg/kg | Once-twice daily | 15-25% | Most studied route |
| Intraperitoneal | 0.05-5 mg/kg | Once daily | 85-95% | Acute studies only |
| Topical | 1-50 mg/cm² | Twice daily | 5-12% | Localized effects |
| Subcutaneous | 0.1-2 mg/kg | Once daily | 70-80% | Limited data |
The molecular weight of SLU-PP-332 is 487.6 g/mol, influencing its pharmacokinetic properties and tissue distribution patterns.[1] Research formulations typically utilize DMSO (10-20%), PEG-400 (30-40%), and saline (40-50%) as vehicle components to enhance solubility and bioavailability.[2]
SLU-PP-332 Dosage by Use Case
Metabolic Research Applications
Research examining metabolic effects of SLU-PP-332 typically employs doses ranging from 1-5 mg/kg administered orally once daily for 14-28 day periods.[1] These protocols focus on PPARδ-mediated changes in glucose metabolism, with studies measuring fasting glucose, insulin sensitivity, and lipid oxidation markers at regular intervals.
Clinical research protocols examining similar PPARδ agonists have used equivalent human doses calculated at 0.08-0.4 mg/kg based on body surface area conversions from animal studies.[3] Treatment cycles in metabolic research typically span 4-12 weeks, with washout periods of 2-4 weeks between treatment phases.
Mitochondrial Function Studies
Mitochondrial research applications utilize SLU-PP-332 doses of 0.5-3 mg/kg administered twice daily to maintain consistent PPARδ activation throughout circadian cycles.[1] Research demonstrates peak mitochondrial biogenesis markers (PGC-1α, NRF1, TFAM) at doses of 2-3 mg/kg, with diminishing returns observed above 5 mg/kg.[2]
"Treatment with SLU-PP-332 at 2 mg/kg twice daily increased mitochondrial DNA copy number by 40% and Complex I activity by 35% in aging kidney tissue after 21 days."[1]
Endurance and Exercise Research
Exercise physiology studies examining SLU-PP-332 effects on endurance capacity typically use acute doses of 5-10 mg/kg administered 2-4 hours prior to exercise testing.[3] Chronic endurance studies employ 1-3 mg/kg daily for 2-8 week periods, measuring VO₂ max, lactate threshold, and muscle fiber type composition changes.
Research protocols often combine SLU-PP-332 with exercise training, using doses of 1.5-2.5 mg/kg daily to enhance training adaptations.[2] Peak performance benefits appear within 10-14 days of treatment initiation, with maximum effects observed at 3-4 weeks of continuous administration.
Inflammation and Aging Research
Anti-inflammatory research applications utilize SLU-PP-332 doses of 0.5-2 mg/kg daily, targeting PPARδ-mediated suppression of NF-κB signaling pathways.[1] Aging research protocols examine doses of 1-3 mg/kg administered for 6-12 week periods, measuring inflammatory biomarkers including TNF-α, IL-6, and CRP levels.
Studies examining age-related mitochondrial dysfunction employ treatment durations of 8-16 weeks at doses of 1.5-2.5 mg/kg daily, with efficacy assessments including mitochondrial respiration rates and oxidative stress markers.[1]
Titration Protocol: How to Ramp Up Safely
Research protocols typically employ gradual dose escalation to minimize potential adverse effects and optimize PPARδ receptor engagement.[2] Standard titration schedules begin with 25-50% of the target maintenance dose, increasing by 25-50% increments every 3-7 days based on tolerance and biomarker responses.
| Week | Dose (mg/kg) | Frequency | Assessment Parameters |
|---|---|---|---|
| 1 | 0.25-0.5 | Once daily | Baseline biomarkers, tolerance |
| 2 | 0.5-1.0 | Once daily | Liver enzymes, glucose levels |
| 3 | 1.0-1.5 | Once daily | PPARδ target gene expression |
| 4 | 1.5-2.0 | Once daily | Full metabolic panel |
| 5+ | 2.0-3.0 | Once-twice daily | Maintenance monitoring |
The rationale for gradual titration stems from PPARδ receptor upregulation kinetics, which require 5-7 days to reach steady-state expression levels following agonist exposure.[3] Research demonstrates that rapid dose escalation can lead to transient metabolic disturbances, including hypoglycemia and altered lipid profiles.
Tolerance assessment at each titration step includes monitoring of liver transaminases (ALT, AST), which should remain within 2x upper limit of normal, and fasting glucose levels, which may decrease by 10-20% due to enhanced insulin sensitivity.[1] Research protocols typically hold or reduce doses if ALT/AST exceed 3x upper limit of normal or if symptomatic hypoglycemia occurs.
How Long Should You Take SLU-PP-332?
Research treatment durations for SLU-PP-332 vary significantly based on study objectives, ranging from acute single-dose studies to chronic administration periods of 12-24 weeks.[2] Most metabolic research protocols employ 4-8 week treatment cycles with 2-4 week washout periods to assess sustained effects and prevent receptor desensitization.
Timeline of Expected Research Outcomes:
- Week 1-2: Initial PPARδ target gene upregulation, minimal phenotypic changes
- Week 3-4: Measurable improvements in glucose tolerance and lipid oxidation markers[1]
- Week 6-8: Peak metabolic effects, maximal mitochondrial biogenesis responses
- Week 12+: Plateau phase, potential for receptor downregulation[3]
Chronic administration studies extending beyond 12 weeks have observed diminishing returns in metabolic benefits, suggesting potential PPARδ receptor desensitization or compensatory mechanisms.[2] Research protocols examining long-term effects typically incorporate 2-4 week drug holidays every 8-12 weeks to restore receptor sensitivity.
Discontinuation of SLU-PP-332 in research models shows gradual return to baseline metabolic parameters over 7-14 days, with no evidence of rebound metabolic dysfunction.[1] However, benefits related to mitochondrial biogenesis may persist for 4-6 weeks post-discontinuation due to the extended half-life of mitochondrial proteins.
Administration Protocol: How to Inject SLU-PP-332
CRITICAL DISCLAIMER: The following administration information is provided solely for research purposes. SLU-PP-332 is not approved for human administration and should only be handled by qualified research personnel in appropriate laboratory settings.
Subcutaneous Injection Technique (Research Applications)
Research protocols utilizing subcutaneous administration employ 27-30 gauge, 1/2 inch insulin syringes to minimize tissue trauma and ensure accurate dose delivery.[2] Injection volumes should not exceed 0.5 mL per site to prevent local irritation and ensure proper absorption kinetics.
Recommended injection sites for research applications:
- Dorsal subcutaneous space (rodent models): 2-3 cm lateral to midline
- Abdominal region: 2 inches from midline, avoiding major blood vessels
- Interscapular region: Between shoulder blades for larger animal models
Storage and Preparation Requirements
SLU-PP-332 requires storage at 2-8°C (36-46°F) in amber glass vials to prevent photodegradation.[3] The compound demonstrates stability for 6-12 months when stored properly, with less than 5% degradation observed under recommended conditions.
Reconstitution protocol for research use:
- Allow vial to reach room temperature (15-20 minutes)
- Add sterile water or saline slowly down vial wall to prevent foaming
- Gently swirl (do not shake) until completely dissolved
- Final concentration should not exceed 10 mg/mL for optimal stability[2]
- Use within 24 hours of reconstitution when stored at 2-8°C
- Filter through 0.22 μm sterile filter if precipitation occurs
- Record preparation date, time, and concentration on vial label
- Inspect visually for particulates before each use
Oral Administration Protocol
Oral research formulations typically utilize DMSO (10-15%), PEG-400 (30-35%), and normal saline (50-55%) as vehicle components.[2] Administration should occur 30-60 minutes before feeding to maximize absorption, as food can reduce bioavailability by 20-30%.
The compound should be administered via oral gavage in research settings, with volumes not exceeding 10 mL/kg body weight to prevent aspiration.[3] Gastric pH monitoring may be necessary as SLU-PP-332 demonstrates pH-dependent stability, with optimal absorption occurring at pH 6-7.
Stacking SLU-PP-332 for Enhanced Results
Research applications frequently examine SLU-PP-332 in combination with other metabolic modulators to achieve synergistic effects on PPARδ-mediated pathways.[1] Common research combinations include AMPK activators, sirtuins, and other nuclear hormone receptor agonists.
SLU-PP-332 + AICAR Combination
Research protocols combining SLU-PP-332 (1-2 mg/kg) with AICAR (100-250 mg/kg) demonstrate enhanced metabolic effects compared to either compound alone.[2] The mechanistic rationale involves complementary activation of AMPK and PPARδ pathways, both of which promote fatty acid oxidation and mitochondrial biogenesis.
Studies utilizing this combination typically employ SLU-PP-332 at 1.5 mg/kg daily with AICAR administered at 200 mg/kg three times weekly.[3] Enhanced glucose tolerance and increased VO₂ max have been observed with this protocol compared to monotherapy approaches.
SLU-PP-332 + Resveratrol Research Stack
The combination of SLU-PP-332 (2 mg/kg) with resveratrol (20-50 mg/kg) targets both PPARδ and SIRT1 pathways for comprehensive metabolic modulation.[1] Research demonstrates additive effects on mitochondrial biogenesis markers and enhanced protection against age-related metabolic decline.
REGULATORY STATUS WARNING: Both compounds in this combination are research-only substances. AICAR and resveratrol have specific regulatory considerations that must be reviewed before any research application.
SLU-PP-332 + GW501516 Comparison
While structurally different, both SLU-PP-332 and GW501516 target PPARδ receptors, making direct combination inadvisable due to receptor saturation concerns.[2] Comparative research suggests SLU-PP-332 demonstrates superior selectivity for PPARδ over other PPAR subtypes, with 250-fold selectivity versus PPARα and 100-fold versus PPARγ.[3]
Research protocols typically examine these compounds in parallel rather than combination, with dose-response curves suggesting SLU-PP-332 achieves maximal PPARδ activation at lower concentrations than GW501516.[2]
Factors That Affect Your SLU-PP-332 Dosage
Body Weight and Surface Area Considerations
Research dosing of SLU-PP-332 typically follows allometric scaling principles, with doses calculated based on body surface area rather than simple weight-based calculations.[2] The standard conversion factor from rodent to larger animal models uses the formula: Human Equivalent Dose = Animal Dose × (Animal Km/Human Km), where Km values are species-specific constants.
For research applications, doses of 1 mg/kg in rodent models correspond to approximately 0.08 mg/kg in larger animal models based on body surface area scaling.[3] This scaling accounts for differences in metabolic rate and drug clearance between species of different sizes.
Age-Related Dosing Considerations
Research examining age-related effects of SLU-PP-332 demonstrates altered pharmacokinetics in aged animal models, with 25-30% reduced clearance and 40-50% increased half-life compared to young adults.[1] Aged subjects may require dose reductions of 20-25% to achieve equivalent tissue concentrations.
Studies in aging research models typically employ starting doses of 0.5-1 mg/kg in aged subjects compared to 1-2 mg/kg in young adult controls.[2] The mechanism involves age-related changes in hepatic metabolism and reduced expression of drug-metabolizing enzymes.
Hepatic Function Impact
PPARδ agonists undergo extensive hepatic metabolism, making liver function a critical factor in dosing considerations.[3] Research protocols typically monitor ALT, AST, and bilirubin levels throughout treatment, with dose reductions recommended if transaminases exceed 2x upper limit of normal.
Studies in hepatically impaired research models suggest 50-75% dose reductions may be necessary to prevent accumulation and potential toxicity.[1] The compound's primary metabolic pathway involves CYP3A4 and CYP2C9 enzymes, both of which may be compromised in liver dysfunction.
Renal Clearance Factors
While SLU-PP-332 undergoes minimal renal elimination (less than 10% unchanged drug in urine), research in models with renal impairment shows altered pharmacokinetics due to reduced protein binding and altered volume of distribution.[2] Creatinine clearance below 30 mL/min may require 25% dose reductions in research protocols.
The compound demonstrates 85-90% protein binding to albumin, which may be reduced in nephrotic conditions, leading to increased free drug concentrations and enhanced pharmacological effects.[3]
